Share
ANN ARBOR, Mich. – EVOQ Therapeutics, Inc. (EVOQ), a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases, today announced a collaboration with JDRF for the development of a new drug platform for antigen-specific immune-tolerizing therapy against Type 1 diabetes (T1D). JDRF’s Industry Discovery and Development Partnership program will support and fund the development of EVOQ’s proprietary NanoDisc platform to develop a next generation immunotherapy against T1D. EVOQ’s technology is engineered to prime the immune system to orchestrate an immune response towards immune tolerance. “This is an exciting time for EVOQ. Having demonstrated pre-clinical efficacy in multiple autoimmune diseases, EVOQ is enthusiastic to work closely with JDRF on Type 1 diabetes,” said William Brinkerhoff, CEO at EVOQ Therapeutics. “JDRF is thrilled to work alongside the dedicated team at EVOQ Therapeutics at this exciting time,” said Joshua A. Vieth, Ph.D., director of research at JDRF. “EVOQ’s NanoDisc platform technology and novel strategy of priming the immune system to orchestrate an immune response towards immune tolerance has the potential to become a transformative immunotherapy for patients suffering from T1D.”
